Achieve Life Sciences
ACHV
15 hedge funds and large institutions have $1.3M invested in Achieve Life Sciences in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.
75% more capital invested
Capital invested by funds: $742K → $1.3M (+$555K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.52% more ownership
Funds ownership: 0.02% → 0.54% (+0.52%)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$1.92M |
| 2 |
AC
Armistice Capital
New York
|
+$632K |
| 3 |
Renaissance Technologies
New York
|
+$367K |
| 4 |
VF
Virtu Financial
New York
|
+$113K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
-$39K |
| 2 |
BBA
BLB&B Advisors
Montgomeryville,
Pennsylvania
|
-$37K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34K |
| 4 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$31K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$13.2K |
ACHV Hedge Fund Activity: Q2 2018 in Review
15 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q2 2018, worth a combined $1.3M — up 75% from $742K a quarter earlier.
Fund positioning in ACHV was balanced in Q2 2018: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Wexford Capital, opening a new position worth an estimated $1.92M. The largest seller was Wellington Shields Capital Management, exiting entirely with an estimated $39K sold.
- 15 institutional investors held Achieve Life Sciences (ACHV) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.3M of Achieve Life Sciences stock for Q2 2018, up 75% quarter-over-quarter.
- 6 funds opened new Achieve Life Sciences positions in Q2 2018 and 6 closed out, a net change of 0 holders.
- The largest Achieve Life Sciences buyer in Q2 2018 was Wexford Capital, an estimated $1.92M added.
- The largest Achieve Life Sciences seller in Q2 2018 was Wellington Shields Capital Management, an estimated $39K sold.
Based on aggregated 13F filings for Q2 2018.